Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165072 · ClinicalTrials.gov registry record
Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury
A clinical trial, sponsored by Texas Tech University Health Sciences Center.
- Completed
- Registry status
- 30
- Enrollment target
NCT02165072: Completed study, sponsored by Texas Tech University Health Sciences Center.
NCT02165072 is a clinical trial that has completed, run by Texas Tech University Health Sciences Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02165072 has completed, sponsored by Texas Tech University Health Sciences Center.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This is an observational study that will examine the possibility of determining the type of Acute Kidney Injury (AKI) using bedside ultrasound machines.
Primary Outcome
The investigators will measure the maximum and minimum diameters of the inferior vena cava with patients with acute kidney injury.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-10 |
What the finished NCT02165072 record still lists
NCT02165072 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02165072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02165072 about?
NCT02165072 is a clinical study titled "Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury". This is an observational study that will examine the possibility of determining the type of Acute Kidney Injury (AKI) using bedside ultrasound machines.
What is the current status of trial NCT02165072?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2014-02. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT02165072?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia